blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4045640

EP4045640 - SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE BETA [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  22.07.2022
Database last updated on 03.09.2024
FormerThe international publication has been made
Status updated on  24.04.2021
Formerunknown
Status updated on  20.11.2020
Most recent event   Tooltip28.10.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
The United States of America, as represented by the Secretary, Department of Health and Human Services
Office of Technology Transfer
National Institutes of Health
6701 Rockledge Drive, Suite 700
MSC 7788, Bethesda
Maryland 20892-7788 / US
[2022/34]
Inventor(s)01 / VENDITTI, Charles P.
13001 Boswell Court
Potomac, Maryland 20854 / US
02 / CHANDLER, Randy J.
3203 Winnett Road
Chevy Chase, Maryland 20815 / US
 [2022/34]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
[2022/34]
Application number, filing date20804709.215.10.2020
[2022/34]
WO2020US55836
Priority number, dateUS201962915347P15.10.2019         Original published format: US 201962915347 P
[2022/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021076797
Date:22.04.2021
Language:EN
[2021/16]
Type: A1 Application with search report 
No.:EP4045640
Date:24.08.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 22.04.2021 takes the place of the publication of the European patent application.
[2022/34]
Search report(s)International search report - published on:EP22.04.2021
ClassificationIPC:C12N9/00, C12N15/86
[2022/34]
CPC:
C12N9/93 (EP,US); C12N15/86 (EP,US); C12Y604/01003 (EP,US);
A61K48/00 (US); C12N2750/14143 (EP,US); C12N2800/22 (EP,US);
C12N2830/50 (US); C12N2840/105 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/34]
TitleGerman:SYNTHETISCHE GENE FÜR DIE BEHANDLUNG VON DURCH MUTATIONEN IN PROPIONYL-COA-CARBOXYLASE-BETA VERURSACHTE PROPIONSÄUREÄMIE[2022/34]
English:SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE BETA[2022/34]
French:GÈNES SYNTHÉTIQUES POUR LE TRAITEMENT DE L'ACIDÉMIE PROPIONIQUE PROVOQUÉE PAR DES MUTATIONS DE LA PROPIONYL-COA CARBOXYLASE BÊTA[2022/34]
Entry into regional phase26.04.2022National basic fee paid 
26.04.2022Designation fee(s) paid 
26.04.2022Examination fee paid 
Examination procedure26.04.2022Examination requested  [2022/34]
26.04.2022Date on which the examining division has become responsible
05.12.2022Amendment by applicant (claims and/or description)
Fees paidRenewal fee
27.10.2022Renewal fee patent year 03
27.10.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XY]WO2016168728  (UNIV EMORY [US], et al) [X] 1-3,5-8,10-12,22,29,30,35,38,44,45,47-49 * claims; page 37, lines 24-27; page 39, lines 8-12; * [Y] 1-56;
 [XY]WO2019104195  (MODERNATX INC [US]) [X] 1-3,5-7,44,47-49,51-53 * example -; claim -; sequence - * [Y] 1-56;
 [XP]WO2020072451  (ULTRAGENYX PHARMACEUTICAL INC [US]) [XP] 1* figures 2, 8-12; examples 5-8; claim - *;
 [Y]  - CHANDLER R J ET AL, "P331 Liver directed gene therapy using AAV9 to treat a new murine model of propionic acidemia caused by Pccb deficiency", HUMAN GENE THERAPY, (20181101), vol. 27, page A124, XP055770020 [Y] 1-56 * abstract *
 [Y]  - MOISE-SILVERMAN J ET AL, "423. Systemic AAV Gene Therapy Rescues Murine Models of Propionic Acidemia Caused Mutations in Pccb from Neonatal Lethality", MOLECULAR THERAPY, (20190401), vol. 27, no. 4S1, page 201, XP055770018 [Y] 1-56 * abstract *
 [YP]  - Chandler R J ET AL, "Mouse Models of, and AAV Gene Therapy for, Propionic Acidemia", 23rd ASGCT Annual Meeting, May 12 - 15, 2020, (20200512), URL: https://cslide-us.ctimeetingtech.com/asgct23/attendee/eposter/file/515#1, (20210128), XP055770005 [YP] 1-56 * abstract, figure 4, figure 5, conclusions; *
 [YP]  - CHANDLER R J ET AL, "250. Mouse Models of, and AAV Gene Therapy for, Propionic Acidemia", MOLECULAR THERAPY, (20200428), vol. 28, no. 4S1, page 118, XP055770006 [YP] 1-56 * abstract *
by applicant   - CHANDLER et al., Mol Ther, (20100000), vol. 18, pages 11 - 6
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.